Regorafenib
Bayer
[]
final integrate-iia results from #gi23: regorafenib improves survival in refractory advanced gej. 12-month survival rate was 19% with regorafenib and 6% for placebo. #ascodailynews has more: #gicsm
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.